​

Aquestive Therapeutics (AQST) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Aquestive Therapeutics Revenue Highlights

Latest Revenue (Y)

$50.58M

Latest Revenue (Q)

$13.54M

Main Segment (Y)

Manufacture and Supply Revenue

Main Geography (Y)

UNITED STATES

Aquestive Therapeutics Revenue by Period

Aquestive Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$50.58M6.09%
2022-12-31$47.68M-6.20%
2021-12-31$50.83M10.87%
2020-12-31$45.85M-12.85%
2019-12-31$52.61M-21.98%
2018-12-31$67.43M0.77%
2017-12-31$66.92M29.22%
2016-12-31$51.78M-

Aquestive Therapeutics generated $50.58M in revenue during NA 2023, up 6.09% compared to the previous quarter, and up 75.02% compared to the same period a year ago.

Aquestive Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$13.54M-32.62%
2024-06-30$20.10M66.76%
2024-03-31$12.05M-8.73%
2023-12-31$13.21M1.57%
2023-09-30$13.00M-1.80%
2023-06-30$13.24M18.92%
2023-03-31$11.13M4.23%
2022-12-31$10.68M-6.81%
2022-09-30$11.46M-13.58%
2022-06-30$13.27M8.11%
2022-03-31$12.27M10.76%
2021-12-31$11.08M-16.63%
2021-09-30$13.29M-13.41%
2021-06-30$15.35M37.97%
2021-03-31$11.12M55.57%
2020-12-31$7.15M-13.45%
2020-09-30$8.26M-61.89%
2020-06-30$21.68M147.29%
2020-03-31$8.77M-46.62%
2019-12-31$16.42M32.22%
2019-09-30$12.42M11.58%
2019-06-30$11.13M-11.98%
2019-03-31$12.64M-24.85%
2018-12-31$16.82M26.81%
2018-09-30$13.27M-4.75%
2018-06-30$13.93M-40.51%
2018-03-31$23.41M91.97%
2017-12-31$12.20M-55.08%
2017-09-30$27.15M143.64%
2017-06-30$11.14M-32.21%
2017-03-31$16.44M-

Aquestive Therapeutics generated $13.54M in revenue during Q3 2024, up -32.62% compared to the previous quarter, and up 102.27% compared to the same period a year ago.

Aquestive Therapeutics Revenue Breakdown

Aquestive Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Manufacture and Supply Revenue$43.80M$36.38M$35.31M$24.88M$38.74M
Co-Development and Research Fees$1.40M$1.29M$1.64M$1.26M$4.04M
License and Royalty Revenue$5.38M$2.35M$5.38M$14.05M$6.96M
Proprietary Product Sales-$7.66M$8.51M$5.65M$2.87M
Royalty-$-916.00K$-1.10M--

Aquestive Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Manufacture and Supply Revenue (86.60%), License and Royalty Revenue (10.63%), and Co-Development and Research Fees (2.77%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Manufacture and Supply Revenue$10.67M$10.52M$11.00M$11.41M$11.64M$9.76M$8.92M$8.41M$9.87M$9.17M$7.69M$10.45M$10.66M$6.51M$4.80M$5.90M$7.26M$6.92M$14.00M$9.15M
Manufactured Product, Other$217.00K-------------------
License and Royalty Revenue$2.16M$1.13M$1.87M$1.10M$1.48M$919.00K$917.00K$376.00K$552.00K$506.00K$380.00K$328.00K$2.36M$373.00K$328.00K$12.93M$426.00K$557.00K$1.36M-
Co-Development and Research Fees$492.00K$403.00K$335.00K$490.00K$124.00K$453.00K$254.00K$395.00K$241.00K$403.00K$218.00K$523.00K$456.00K$394.00K$1.18M-----
Proprietary Product Sales------$589.00K$2.28M$2.60M$2.19M$2.79M$1.99M$1.91M$1.58M$682.00K-----
Royalty------$-13.00K$-25.00K------------

Aquestive Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Manufacture and Supply Revenue (78.80%), License and Royalty Revenue (15.97%), Co-Development and Research Fees (3.63%), and Manufactured Product, Other (1.60%).

Aquestive Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
UNITED STATES$37.10M$39.92M$42.86M--
Non-US$13.48M$7.76M$7.97M$4.89M$4.32M
United States---$40.96M$48.29M

Aquestive Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (73.35%), and Non-US (26.65%).

Quarterly Revenue by Country

CountrySep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Dec 20Dec 19Dec 18Sep 18Jun 18
UNITED STATES$10.53M$10.43M$11.73M$9.89M$7.31M$8.16M$8.51M$9.08M$11.26M$11.08M$9.37M$10.53M$13.11M-----
Non-US$3.01M$1.63M$1.47M$3.11M$5.93M$2.97M$2.18M$2.38M$2.01M$1.19M$1.71M$2.76M$2.24M$1.69M$1.81M---
United States-------------$5.46M$14.61M$15.51M$12.48M$13.38M

Aquestive Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (77.74%), and Non-US (22.26%).

Aquestive Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ALKSAlkermes$1.66B$378.14M
LNTHLantheus$1.30B$378.73M
AMPHAmphastar Pharmaceuticals$593.24M$188.82M
ANIPANI Pharmaceuticals$486.82M$148.33M
IRWDIronwood Pharmaceuticals$442.74M$91.59M
ORGOOrganogenesis$433.14M$115.18M
DVAXDynavax$232.28M$79.34M
LFCRLifecore Biomedical$128.26M$24.70M
AQSTAquestive Therapeutics$50.58M$13.54M
EVOKEvoke Pharma$5.18M$2.65M
SHPHShuttle Pharmaceuticals--

AQST Revenue FAQ

What is Aquestive Therapeutics’s yearly revenue?

Aquestive Therapeutics's yearly revenue for 2023 was $50.58M, representing an increase of 6.09% compared to 2022. The company's yearly revenue for 2022 was $47.68M, representing a decrease of -6.20% compared to 2021. AQST's yearly revenue for 2021 was $50.83M, representing an increase of 10.87% compared to 2020.

What is Aquestive Therapeutics’s quarterly revenue?

Aquestive Therapeutics's quarterly revenue for Q3 2024 was $13.54M, a -32.62% decrease from the previous quarter (Q2 2024), and a 4.15% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $20.1M, a 66.76% increase from the previous quarter (Q1 2024), and a 51.79% increase year-over-year (Q2 2023). AQST's quarterly revenue for Q1 2024 was $12.05M, a -8.73% decrease from the previous quarter (Q4 2023), and a 8.25% increase year-over-year (Q1 2023).

What is Aquestive Therapeutics’s revenue growth rate?

Aquestive Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -0.49%, and for the last 5 years (2019-2023) was -3.85%.

What are Aquestive Therapeutics’s revenue streams?

Aquestive Therapeutics's revenue streams in c 23 are Manufacture and Supply Revenue, Co-Development and Research Fees, and License and Royalty Revenue. Manufacture and Supply Revenue generated $43.8M in revenue, accounting 86.60% of the company's total revenue, up 20.42% year-over-year. Co-Development and Research Fees generated $1.4M in revenue, accounting 2.77% of the company's total revenue, up 8.43% year-over-year. License and Royalty Revenue generated $5.38M in revenue, accounting 10.63% of the company's total revenue, up 128.67% year-over-year.

What is Aquestive Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Aquestive Therapeutics was Manufacture and Supply Revenue. This segment made a revenue of $43.8M, representing 86.60% of the company's total revenue.